EUVIMEDEUVIMED entdecken
Crossref

METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC

Lianlian Liu iD, Tingting Zhao, Siyi Zheng, Dongxiao Tang, Hui Han iD, Chunlong Yang, Xin Zheng, Juan Wang, Jieyi Ma, Wei Wei, Zhaoyu Wang, Shuqi He und 1 weitere

Oral Diseases · 2024

DOI: 10.1111/odi.14864 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oral Diseases, 2024. Verfasst von Lianlian Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Indoles, Quinolines, Mouth Neoplasms, Apoptosis. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the inhibitory effects of STM2457, which is a novel METTL3 (m 6 A writer) inhibitor, both as a monotherapy and in combination with anlotinib, in the treatment of oral squamous cell carcinoma (OSCC) both in vitro and in vivo. Materials and Methods The efficacy of STM2457 or STM2457 plus anlotinib was evaluated using two OSCC cell lines by CCK8, transwell, colony formation, would‐healing, sphere formation, cell cycle, apoptosis assays, and nude mice tumor xenograft techniques. The molecular mechanism study was carried out by western blotting, qRT‐PCR, MeRIP‐qPCR, immunofluorescence, and immunohistochemistry.

Results

STM2457 combined with anlotinib enhanced inhibition of cellular survival/proliferation and promotion of apoptosis in vitro. Moreover, this combinatorial approach exerted a notable reduction in stemness properties and EMT (epithelial‐mesenchymal transition) features of OSCC cells. Remarkably, in vivo studies validated the efficacy of the combination treatment. Mechanistically, our investigations revealed that the combined action of STM2457 and anlotinib exerted downregulatory effects on EGFR (epidermal growth factor receptor) expression in OSCC cells.

Conclusions

The combination of STM2457 and anlotinib targeting EGFR exerted a multiple anti‐tumor effect. In near future, anlotinib combined with STM2457 may provide a novel insight for the treatment of OSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesQuinolinesMouth NeoplasmsApoptosisMice, NudeCell ProliferationHumansAnimalsCell Line, TumorMiceCarcinoma, Squamous CellEpithelial-Mesenchymal TransitionErbB ReceptorsAntineoplastic AgentsXenograft Model Antitumor AssaysMethyltransferases

Stichwörter der Autor:innen

EGFRSTM2457anlotiniboral squamous cell carcinoma

Substanzen

anlotinibIndolesQuinolinesMETTL3 protein, humanErbB ReceptorsAntineoplastic AgentsMethyltransferases

Autor:innen und Institutionen

  • Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • College & Hospital of Stomatology, Guangxi Medical University, Nanning, China.
  • Center for Translational Medicine, Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Clinical Research Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
  • Division of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Laboratory of General Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

ORCID-Profile: Lianlian Liu, Hui Han, Qianting He

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, L., Zhao, T., Zheng, S., Tang, D., Han, H., Yang, C., Zheng, X., Wang, J., Ma, J., Wei, W., Wang, Z., He, S., & He, Q. (2024). METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC. Oral Diseases. https://doi.org/10.1111/odi.14864

Vancouver

Liu L, Zhao T, Zheng S, Tang D, Han H, Yang C, et al. METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC. Oral Diseases. 2024. doi:10.1111/odi.14864

BibTeX
@article{Liu2024,
  author = {Liu, Lianlian and Zhao, Tingting and Zheng, Siyi and Tang, Dongxiao and Han, Hui and Yang, Chunlong and Zheng, Xin and Wang, Juan and Ma, Jieyi and Wei, Wei and Wang, Zhaoyu and He, Shuqi and He, Qianting},
  title = {METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC},
  journal = {Oral Diseases},
  year = {2024},
  doi = {10.1111/odi.14864}
}
Kostenlos starten →